Trial · NCT06992674
The R-E-V-I-V-A-L Study
NCT06992674, Phase 2, Active not recruiting, Second Affiliated Hospital, Zhejiang University, School of Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The R-E-V-I-V-A-L Study. Trials, record NCT06992674. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06992674
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The R-E-V-I-V-A-L Study
- NCT number
- NCT06992674
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 240 participants, estimated
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Conditions
- Vestibular Migraine
- Interventions
- Rimegepant, Placebo
- First posted
- 2025-05-28
- Last updated
- 2025-06-25
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Moderate/Severe vestibular symptom days | from baseline to weeks 12-16 | Change in number of Moderate/Severe vestibular symptom days as defined by Barany Society1 for participants measured daily from the observational phase compared to weeks 12-16. |
| Secondary | Moderate/Severe vestibular symptom days | every 4 weeks during the 12-week treatment period compared to baseline | Change in number of Moderate/Severe vestibular symptom days as defined by Barany Society1 every 4 weeks during the 12-week treatment period compared to baseline |
| Secondary | the number of vestibular symptom attacks | every 4 weeks compared to baseline over the 12-week treatment period | Change in the number of vestibular symptom attacks every 4 weeks compared to baseline over the 12-week treatment period. (Since VM attacks may recur multiple times within a day, each lasting a short duration, we need to further clearly define what constitutes "one attack.") |
| Secondary | MMD | every 4 weeks compared to baseline over the 12-week treatment period | Change in the number of monthly migraine days (MMD) every 4 weeks compared to baseline over the 12-week treatment period |
| Secondary | MIDAS | from baseline to week 16 | Change in Migraine Disability Assessment (MIDAS) score from baseline to week 16 |
| Secondary | percentage reduction in moderate/severe vestibular symptom days | from baseline to weeks 12-16 | Change in response rate (100%,75%,50%,25%,0%) by percentage reduction in moderate/severe vestibular symptom days from baseline to weeks 12-16 |
| Secondary | DHI | from baseline to week 16 | Change in dizziness handicap inventory (DHI) score from baseline to week 16 |
| Secondary | VADL | from baseline to week 16 | Change in Vestibular Activities of Daily Living Scale (VADL) score from baseline to week 16 |
| Secondary | PHQ-9 | from baseline to week 16 | Change in Patient Health Questionnaire-9 (PHQ-9) score from baseline to week 16 |
| Secondary | GAD-7 | from baseline to week 16 | Change in General Anxiety Disorder-7 (GAD-7) score from baseline to week 16 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers9
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06992674
GET https://conductscience.org/api/trials/v1/NCT06992674/registered